FSH vs PT-141

Binds FSH receptors on Sertoli cells in testes to support sperm maturation and inhibin B production. In women, binds granulosa cell FSH receptors to drive follicular growth and estradiol production.

FSH (follicle-stimulating hormone) is an endogenous heterodimeric glycoprotein hormone produced and secreted by pituitary gonadotrophs, composed of a non-covalently associated common alpha subunit shared with LH, TSH, and hCG, and a unique FSH-specific beta subunit that confers receptor specificity; it is the primary regulator of gametogenesis in both sexes, acting on ovarian granulosa cells and testicular Sertoli cells to drive reproductive development. FSH activates its cognate receptor (FSHR) through cAMP-mediated signaling to stimulate follicular maturation and estradiol synthesis in the ovary via aromatase upregulation, and to support spermatogenesis in the testis by promoting Sertoli cell function and germ cell proliferation; FSH levels rise dramatically at menopause as negative feedback from ovarian estrogen declines. A Cochrane systematic review and meta-analysis established that recombinant FSH preparations are clinically equivalent to urinary-derived gonadotropins for ovarian stimulation in assisted reproductive technology cycles, providing the evidence base underlying current ART practice; this review supports the use of recombinant FSH as the standard of care for controlled ovarian hyperstimulation. FDA-approved recombinant FSH preparations — follitropin alfa (Gonal-f) and follitropin beta (Follistim) — require a prescription and are indicated for ovulation induction and ART in women and for hypogonadotropic hypogonadism in men; endogenous FSH is not administered as a therapeutic agent, and research-grade recombinant FSH is used as a cell culture tool and reproductive biology research compound.

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and the first centrally acting peptide approved by the FDA for a sexual dysfunction indication — marketed as Vyleesi (Palatin Technologies / AMAG Pharmaceuticals) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally through vascular smooth muscle relaxation, PT-141 acts centrally via melanocortin MC3R and MC4R receptors in the hypothalamus to modulate sexual motivation and arousal pathways — a mechanistically distinct approach that is effective regardless of vascular status. Pivotal Phase 3 RCTs in premenopausal women with HSDD demonstrated statistically significant improvements in satisfying sexual events and desire scores versus placebo, establishing the clinical evidence base for FDA approval in 2019. PT-141 dosage: the FDA-approved dose is 1.75mg administered as a single subcutaneous injection in the abdomen using an auto-injector device, approximately 45 minutes before anticipated sexual activity; it should not be used more than once per 24 hours or more than 8 times per month per prescribing guidance. Compounded PT-141 — available through licensed compounding pharmacies — is commonly prepared in 10mg vials for research contexts; typical compounded doses range from 1–2mg per use. PT-141 nasal spray formulations have been investigated as an alternative delivery route, though the approved form is subcutaneous injection. PT-141 for men: while FDA approval is limited to premenopausal women with HSDD, PT-141 is used off-label in men for sexual dysfunction, including cases where PDE5 inhibitors are insufficient or contraindicated; the central mechanism of action is not sex-specific. Side effects: the most common adverse effect is nausea (reported in approximately 40% of subjects in pivotal trials), followed by flushing, headache, and transient hyperpigmentation with repeated use. A transient increase in blood pressure is observed in the first hour post-injection; PT-141 is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. PT-141 (Vyleesi) is FDA-approved and requires a prescription; compounding pharmacy access also requires a prescription. Providers offering PT-141 consultations — including telehealth platforms — can be found in the PeptideBase directory.